XLXiaotong Li

Xiaotong Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaotong Li has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Long Yu Hu

    State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen, Fujian, P.R. China

    2 shared publications
  • Zhen Hua Wu

    State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen, Fujian, PR China

    2 shared publications
  • Da Qian Xu

    School of Life Sciences, Xiamen University, Xiamen, Fujian, P.R. China

    1 shared publication
  • Huanhuan Ma

    State Key Laboratory of Liver Research, The University of Hong Kong

    1 shared publication
  • Lianzhong Luo

    Central Laboratory, Xiamen Medical College, Xiamen, Fujian 361008, China

    1 shared publication
  • Meijun Jin

    State Key Laboratory for Cellular Stress Biology, School of Life Sciences, Xiamen University, Fujian 361102, China

    1 shared publication

Latest Publications

  • Open Access

    C-terminus of MUC16 activates Wnt signaling pathway through its interaction with β-catenin to promote tumorigenesis and metastasis

    by Qi Liu, Zhen Cheng, Lianzhong Luo, Yun Yang, Zhenzhu Zhang, Huanhuan Ma, Tao Chen, Xi Huang, Shu-Yong Lin, Meijun Jin, et al.

    C-terminus of MUC16 activates Wnt signaling pathway through its interaction with β-catenin to promote tumorigenesis and metastasis C-terminus of MUC16 activates Wnt signaling pathway through its interaction with β-catenin to promote tumorigenesis and metastasis


  • Open Access

    Praziquantel Synergistically Enhances Paclitaxel Efficacy to Inhibit Cancer Cell Growth

    by Zhen Hua Wu, Ming-Ke Lu, Long Yu Hu, Xiaotong Li

    The major challenges we are facing in cancer therapy with paclitaxel (PTX) are the drug resistance and severe side effects. Massive efforts have been made to overcome these clinical challenges by combining PTX with other drugs. In this study, we reported the first preclinical data that praziquantel (PZQ), an anti-parasite agent, could greatly enhance the anticancer efficacy of PTX in various cancer cell lines, including PTX-resistant cell lines. Based on the combination index value, we demonstrated that PZQ synergistically enhanced PTX-induced cell growth inhibition. The co-treatment of PZQ and PTX also induced significant mitotic arrest and activated the apoptotic cascade. Moreover, PZQ combined with PTX resulted in a more pronounced inhibition of tumor growth compared with either drug alone in a mouse xenograft model. We tried to investigate the possible mechanisms of this synergistic efficacy induced by PZQ and PTX, and we found that the co-treatment of the two drugs could markedly decrease expression of X-linked inhibitor of apoptosis protein (XIAP), an anti-apoptotic protein. Our data further demonstrated that down-regulation of XIAP was required for the synergistic interaction between PZQ and PTX. Together, this study suggested that the combination of PZQ and PTX may represent a novel and effective anticancer strategy for optimizing PTX therapy.


  • A Cell-Based Assay for Screening Spindle Checkpoint Inhibitors

    by Zhen Hua Wu, Long Yu Hu, Da Qian Xu, Xiaotong Li

    In eukaryotes, the spindle checkpoint acts as a surveillance mechanism that ensures faithful chromosome segregation. The spindle checkpoint prevents premature separation of sister chromatids and the onset of anaphase until every chromosome is properly attached to the mitotic spindle. Tumorigenesis might result from generation of aneuploidy by dysfunction of the spindle checkpoint. Differences of the checkpoint system in normal cells versus tumor cells might provide a new opportunity in cancer drug development; therefore, efforts to identify the spindle checkpoint inhibitors have been fostered. Based on spindle checkpoint inhibitors being able to induce cells to exit mitotic arrest caused by microtubule drug treatment, we developed a cell-based assay to screen compounds that were potential spindle checkpoint inhibitors. This assay was validated with a known spindle checkpoint inhibitor and was easy to adapt to a large-scale screening. It also had the advantages of being high in sensitivity and low in cost.